Genmab A/S
NASDAQ:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
NASDAQ:GMAB
Watchlist
Price: 20.59 USD 0.24% Market Closed
Market Cap: 13.1B USD

Relative Value

The Relative Value of one GMAB stock under the Base Case scenario is 32.2 USD. Compared to the current market price of 20.59 USD, Genmab A/S is Undervalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GMAB Relative Value
Base Case
32.2 USD
Undervaluation 36%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
66
Median 3Y
9.6
Median 5Y
13.4
Industry
7
Forward
3.5
vs History
96
vs Industry
10
Median 3Y
31.9
Median 5Y
32.4
Industry
21.8
Forward
12.2
vs History
96
vs Industry
13
Median 3Y
25.7
Median 5Y
27.9
Industry
19.3
vs History
96
vs Industry
11
Median 3Y
27.7
Median 5Y
30.5
Industry
22.7
vs History
96
vs Industry
38
Median 3Y
5.3
Median 5Y
6.6
Industry
2.4
vs History
96
vs Industry
61
Median 3Y
8.1
Median 5Y
11.8
Industry
7.3
Forward
2.7
vs History
38
vs Industry
64
Median 3Y
4
Median 5Y
0
Industry
8.8
vs History
96
vs Industry
12
Median 3Y
21.7
Median 5Y
22.1
Industry
4
Forward
7.3
vs History
96
vs Industry
10
Median 3Y
21.7
Median 5Y
22.8
Industry
3.7
Forward
8.1
vs History
96
vs Industry
14
Median 3Y
22.1
Median 5Y
24.2
Industry
4.5
vs History
96
vs Industry
10
Median 3Y
23.4
Median 5Y
25.6
Industry
3.2
vs History
96
vs Industry
42
Median 3Y
17.8
Median 5Y
22.8
Industry
4.5

Multiples Across Competitors

GMAB Competitors Multiples
Genmab A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Genmab A/S
NASDAQ:GMAB
85.6B USD 4 10.9 8.7 9.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 893 126.3 -165 841.9 -201 384.9 -199 086.8
US
Abbvie Inc
NYSE:ABBV
328.4B USD 5.8 77.5 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
150.8B USD 4.5 36.9 15.2 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
128.5B USD 4.5 267.8 10.6 13.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.9B USD 11.5 -236.9 25.9 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 019 -515.2 -561 -546
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66B USD 4.7 15 9.4 10.5
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -58
NL
argenx SE
XBRU:ARGX
32.7B EUR 17 44.6 -2 522 -1 690.9
P/S Multiple
Revenue Growth P/S to Growth
DK
Genmab A/S
NASDAQ:GMAB
Average P/S: 3 172 292.9
4
16%
0.2
FR
Pharnext SCA
OTC:PNEXF
34 893 126.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.5
10%
1.2
US
E
Epizyme Inc
F:EPE
2 019
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
17
39%
0.4
P/E Multiple
Earnings Growth PEG
DK
Genmab A/S
NASDAQ:GMAB
Average P/E: 68.6
10.9
10%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 841.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.5
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
267.8
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -236.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
44.6
28%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Genmab A/S
NASDAQ:GMAB
Average EV/EBITDA: 14.6
8.7
20%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 384.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 522 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Genmab A/S
NASDAQ:GMAB
Average EV/EBIT: 18.8
9.2
19%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 086.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 690.9 N/A N/A